Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imati... von Hughes, Timothy P, Hochhaus, Andreas, Kantarjian, Hagop M, Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D, Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D, Kemp, Charisse, Larson, Richard A, Saglio, Giuseppe

Volltext

Effect of Clopidogrel on the Steady-State Pharmacokinetics of Fluvastatin von Ayalasomayajula, Surya P., Vaidyanathan, Sujata, Kemp, Charisse, Prasad, Pratapa, Balch, Alfred, Dole, William P.

Volltext

Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2‐Arm, Crossover, Randomized, Open‐Label Study in Healthy Volunteers von Menssen, Hans D., Quinlan, Michelle, Kemp, Charisse, Tian, Xianbin

Volltext

Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Op... von Mauro, Michael, Boquimpani, Carla, Minami, Yosuke, Réa, Delphine, Kemp, Charisse, Hsu Schmitz, Shu-Fang, Gopalakrishna, Prashanth, Hochhaus, Andreas

Volltext

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles von Beaumont, Jennifer L, Magestro, Matthew, Coombs, John, Fan, Xiaolin, Kemp, Charisse, Waltzman, Roger J.

Volltext

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM) von Larson, Richard A., Kim, Dong-Wook, Jootar, Saengsuree, Pasquini, Ricardo, Clark, Richard E., Lobo, Clarisse, Goldberg, Stuart L., Shibayama, Hirohiko, Hochhaus, Andreas, Saglio, Giuseppe, Kantarjian, Hagop M., Kemp, Charisse, Deng, Weiping, Menssen, Hans D., Hughes, Timothy P.

Volltext

Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENE... von Delphine, Rea, Gautier, Jean-francois, Breccia, Massimo, Saglio, Giuseppe, Hughes, Timothy P., Kantarjian, Hagop M., Kemp, Charisse, Gao, Haitao, Piccolo, Carmen, Larson, Richard A., Hochhaus, Andreas

Volltext

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Respons... von Saglio, Giuseppe, Hochhaus, Andreas, Hughes, Timothy P., Clark, Richard E., Nakamae, Hirohisa, Kim, Dong-Wook, Jootar, Saengsuree, Etienne, Gabriel, Flinn, Ian, Lipton, Jeffrey H., Pasquini, Ricardo, Moiraghi, Beatriz, Kemp, Charisse, Fan, Xiaolin, Menssen, Hans D., Kantarjian, Hagop M., Larson, Richard A.

Volltext

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update von Larson, Richard A., Hochhaus, Andreas, Saglio, Giuseppe, Kim, Dong-Wook, Jootar, Saengsuree, Le Coutre, Philipp D., Reiffers, Josy, Pasquini, Ricardo, Goldberg, Stuart L., Clark, Richard E., Kemp, Charisse N., Fan, Xiaolin, Menssen, Hans D., Hughes, Timothy P., Kantarjian, Hagop M.

Volltext

Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (C... von Saglio, Giuseppe, Hughes, Timothy P., Larson, Richard A., Issaragrilsil, Surapol, Turkina, Anna G., Steegmann, Juan Luis, Lopez, Jose L., Nakaseko, Chiaki, Kalaycio, Matt E., Huguet, Francoise, Kemp, Charisse N., Fan, Xiaolin, Menssen, Hans D., Kantarjian, Hagop M., Hochhaus, Andreas

Volltext

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatin... von Hughes, Timothy P, Hochhaus, Andreas, Kantarjian, Hagop M, Cervantes Requena, F, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D, Rosti, Gianantonio, Ossenkoppele, Gert J, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D, Kemp, Charisse, Larson, Richard A, Saglio, Giuseppe

Volltext

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatin... von Hughes, Timothy P, Hochhaus, Andreas, Kantarjian, Hagop M, Cervantes Requena, F, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D, Rosti, Gianantonio, Ossenkoppele, Gert J, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D, Kemp, Charisse, Larson, Richard A, Saglio, Giuseppe

Volltext

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in... von Kantarjian, Hagop M., Kim, Dong-Wook, Issaragrisil, Surapol, Clark, Richard E, Reiffers, Josy, Nicolini, Franck E., Pasquini, Ricardo, Kalaycio, Matt, Hughes, Timothy P., Hochhaus, Andreas, Kemp, Charisse, Fan, Xiaolin, Waltzman, Roger J., Saglio, Giuseppe, Larson, Richard A.

Volltext

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From... von Hochhaus, Andreas, Hughes, Timothy P., Saglio, Giuseppe, Guilhot, François, Al-Ali, Haifa Kathrin, Rosti, Giantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kemp, Charisse, Fan, Xiaolin, Hoenekopp, Albert, Larson, Richard A., Kantarjian, Hagop M.

Volltext

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u) von Kantarjian, Hagop, Flinn, Ian W., Goldberg, Stuart, Bunworasate, Udomsak, Zanichelli, Maria Aparecida, Nakamae, Hirohisa, Hughes, Timothy P., Hochhaus, Andreas, Saglio, Giuseppe, Woodman, Richard Charles, Blakesley, Rick E., Kemp, Charisse N., Kalaycio, Matt E., Larson, Richard A.

Volltext